<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242839</url>
  </required_header>
  <id_info>
    <org_study_id>CT08L06UC</org_study_id>
    <nct_id>NCT01242839</nct_id>
  </id_info>
  <brief_title>Randomized Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing</brief_title>
  <acronym>UNICOL</acronym>
  <official_title>Randomized Multicentric Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organ, Tissue, Regeneration, Repair and Replacement</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Organ, Tissue, Regeneration, Repair and Replacement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CACICOL20 is a biodegradable nanopolymer engineered to mimic glycosaminoglycans such as
      heparan sulfates. Applied to the corneal lesion, it replaces damaged heparan sulfates in the
      matrix scaffold. CACICOL20 binds to matrix proteins such as collagen and cytokines or
      endogenous growth factors of the cellular microenvironment. CACICOL20 provides a protective
      function and restores the matrix architecture. This produces a suitable spatial environment
      for cells to respond properly to the cascade of signals needed for tissue regeneration to
      resume.

      The ophthalmic solution, CACICOL20, used for corneal ulcers is very well tolerated both
      locally and generally, as proved by a pilot study which as been conducted at the &quot;Hôpital des
      XV-XX&quot; in Paris (France). It reduces the pain significantly and increases corneal ulcer
      healing (all ulcers treated were resistant to all other usual therapies).

      Therefore, the accuracy of a Randomized multicentric double blinded study to evaluate the
      efficacy of CACICOL20 versus placebo for chronic corneal ulcer healing has been shown and
      will begin mid-may 2010. In this study, CACICOL20 will be applied every 2 or 4 days for 3
      months.

      The aim of the study is a double blinded comparison of complete chronic corneal ulcers
      healing rate within 3 months in 3 groups of patient double blinded randomized between
      CACICOL20 instillations distribution and physiological salt solution instillations
      distribution.

      The main judgment criteria is healing rate within 3 months defined as corneal ulcer complete
      closure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing rate</measure>
    <time_frame>Within 1 months</time_frame>
    <description>The main judgment criteria is healing rate within 3 months defined as corneal ulcer complete closure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healing rate</measure>
    <time_frame>2 and 3 months</time_frame>
    <description>Complete Healing rate of the ulcer at 1 and 2 months defined as corneal ulcer complete closure, the evaluation of the pain with visual pain scale and evaluation of the quotation of analgesic treatments used by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual pain scale</measure>
    <time_frame>1, 2 and 3 months</time_frame>
    <description>Complete Healing rate of the ulcer at 1 and 2 months defined as corneal ulcer complete closure, the evaluation of the pain with visual pain scale and evaluation of the quotation of analgesic treatments used by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated treatments quotation</measure>
    <time_frame>1, 2 and 3 months</time_frame>
    <description>Quotation of analgesic treatments used and assessment of the effects of lubricant eye drops on the patient.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Corneal Ulcer</condition>
  <arm_group>
    <arm_group_label>CACICOL20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CACICOL20 and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CACICOL20</intervention_name>
    <description>CACICOL20 is a solution of dextran &amp; poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.</description>
    <arm_group_label>CACICOL20</arm_group_label>
    <arm_group_label>CACICOL20 and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-infectious, corneal chronic ulcer, painful or not ,whose depth does
             not exceed the superficial stroma.

          -  Resistance of corneal pathology to standard treatment: eye drops to promote healing,
             tear substitutes, anti-inflammatory drugs, cyclosporin.

          -  Patients previously treated for the corneal pathology, assessed ineffective or
             Insufficiently effective by the investigator

          -  Patients using wetting gel or eye drops without conservator during the inclusion

          -  Anti-inflammatory local treatments must be stopped for at least 8 days.

          -  No contact lenses or lenses must be removed for at least 8 days.

          -  Age of inclusion ≥ 18 years.

          -  Written and signed informed consent from patient.

          -  Realization of a preliminary medical examination.

          -  Covers by social insurance

        Exclusion Criteria:

          -  Ulcers deeper than the superficial stroma, perforated ulcers or pre-perforated

          -  Corneal abscess

          -  Infectious and progressive ulcerative keratitis

          -  Patients receiving anti-inflammatory eye drops or steroid with cyclosporine treatment
             (in this case, possibility of inclusion in the clinical protocol after a Case
             &quot;wash-out of 8 days)

          -  Patients on long-term eye drops containing preservatives and can not be stopped or
             replaced by an equivalent without preservatives

          -  Patients on systemic anti-inflammatory, anti-allergic, psychotropic or antibiotics
             therapies, modified since less than 10 days or likely to be on short-term

          -  Wearing contact lenses if patient has not been stopped at least eight days before the
             start of the protocol

          -  ocular surgery within the last 3 months

          -  patient already included in another clinical trial with an investigational product

          -  Pregnant patients or breastfeeding

          -  Person under a legal protection measure, under guardianship

          -  Unable to follow up medical examinations for geographical, social or psychological
             reasons

          -  Not cover by social insurance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Baudouin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>XV- XX Hospital - Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicennes</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Ambroise Paré</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied - CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital BICETRE</name>
      <address>
        <city>Le Kremlin-bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges, Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU LYON, Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Hôtel-Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier des Quinze Vingt</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital BICHAT - CLAUDE-BERNARD</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopitaux de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint Louis, Saint Jean d'Angély</name>
      <address>
        <city>Saint Jean d'Angély</city>
        <zip>17415</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint-Etiennne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2010</study_first_posted>
  <last_update_submitted>May 4, 2016</last_update_submitted>
  <last_update_submitted_qc>May 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CACICOL20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Corneal Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

